Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Healthtrust
Colorcon
US Department of Justice
Fuji
Novartis
Mallinckrodt
Deloitte
Boehringer Ingelheim
Merck

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,773,714

« Back to Dashboard

Which drugs does patent 6,773,714 protect, and when does it expire?

Patent 6,773,714 protects ELIGARD and is included in four NDAs.

This patent has fifty-eight patent family members in twenty-six countries.
Summary for Patent: 6,773,714
Title: Polymeric delivery formulations of leuprolide with improved efficacy
Abstract:The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.
Inventor(s): Dunn; Richard L. (Fort Collins, CO), Garrett; John Steven (Fort Collins, CO), Ravivarapu; Harish (Union City, CA), Chandrashekar; Bhagya L. (Scarborough, ME)
Assignee: Atrix Laboratories, Inc. (Fort Collins, CO)
Application Number:10/373,400
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Use; Device;

Drugs Protected by US Patent 6,773,714

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021343-001 Jan 23, 2002 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING CANCER ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING CANCER ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021488-001 Feb 13, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING CANCER ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING CANCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,773,714

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,314 Controlled release liquid delivery compositions with low initial drug burst ➤ Sign Up
8,470,359 Sustained release polymer ➤ Sign Up
9,539,333 Sustained release polymer ➤ Sign Up
8,486,455 Polymeric delivery formulations of leuprolide with improved efficacy ➤ Sign Up
9,254,307 Polymeric delivery formulations of leuprolide with improved efficacy ➤ Sign Up
9,283,282 Sustained release polymer ➤ Sign Up
8,840,916 Sustained release polymer ➤ Sign Up
6,565,874 Polymeric delivery formulations of leuprolide with improved efficacy ➤ Sign Up
6,630,155 Controlled release liquid delivery compositions with low initial drug burst ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,773,714

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 259217 ➤ Sign Up
Austria 296088 ➤ Sign Up
Austria 458469 ➤ Sign Up
Australia 1331200 ➤ Sign Up
Australia 2001292931 ➤ Sign Up
Australia 2006241376 ➤ Sign Up
Australia 2010201645 ➤ Sign Up
Australia 9293101 ➤ Sign Up
Brazil 0114069 ➤ Sign Up
Brazil PI0114069 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Queensland Health
McKinsey
Harvard Business School
Citi
US Army
Chinese Patent Office
Farmers Insurance
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot